Ameriprise’s Adverum Biotechnologies ADVM Stock Holding History

Ameriprise’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,039	Closed	-$38K	–	3952
2022 Q3	$38K	Buy	+4,039	New	+$53.1K	﹤0.01%	3903
2020 Q1	–	Sell	-4,309	Closed	-$496K	–	3632
2019 Q4	$496K	Sell	4,309 -2,738	-39%	-$241K	﹤0.01%	3330
2019 Q3	$384K	Sell	7,047 -13,702	-66%	-$1.54M	﹤0.01%	3379
2019 Q2	$2.47M	Sell	20,749 -6,333	-23%	-$524K	﹤0.01%	2618
2019 Q1	$1.42M	Buy	27,082 +11,071	+69%	+$448K	﹤0.01%	2901
2018 Q4	$505K	Buy	+16,011	New	+$651K	﹤0.01%	3181

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise's ADVM Position: Q4 2022 in Review

Ameriprise sold out of Adverum Biotechnologies (ADVM) in Q4 2022, closing a stake of 4,039 shares — an estimated $38K sold.

Ameriprise first reported a position in ADVM in Q4 2018 and held it in 6 quarters. The position peaked at $2.47M in Q2 2019. 59 funds tracked by Wall St. Rank hold ADVM as of Q4 2022.

Ameriprise reported no remaining Adverum Biotechnologies position as of Q4 2022 after selling out during the quarter.
Ameriprise sold 4,039 Adverum Biotechnologies shares in Q4 2022, an estimated $38K.
Ameriprise first reported a position in Adverum Biotechnologies in Q4 2018 and held it in 6 quarters.
Ameriprise's Adverum Biotechnologies position peaked at $2.47M in Q2 2019.
59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2022.

Based on Ameriprise's 13F filing for Q4 2022, filed 14 Feb 2023.